• EdU Imaging Kits (Cy5): 5 Practical Lab Scenarios

  2026-08-08

  This scenario-based guide explains how EdU Imaging Kits (Cy5), SKU K1076, can support reproducible S-phase DNA synthesis measurement in microscopy and flow cytometry workflows. It connects assay design, optimization, interpretation, and vendor selection to practical challenges in proliferation, cytotoxicity, and genotoxicity studies.

• How Cholesterol Traps Lipid Nanoparticles

  2026-08-07

  Luo and colleagues developed a sensitive tracking platform to follow nucleic-acid-loaded lipid nanoparticles through intracellular compartments. Their results indicate that excess cholesterol, rather than ionizable-lipid content alone, promotes peripheral early-endosome aggregation that limits endolysosomal trafficking and reduces cargo delivery.

• Rapamycin (Sirolimus) SKU A8167: Reliable mTOR Inhibition in

  2026-08-07

  This article delivers scenario-driven insights for leveraging Rapamycin (Sirolimus) (SKU A8167) in cell viability, proliferation, and cytotoxicity assays. Grounded in recent literature and practical laboratory challenges, it demonstrates how APExBIO’s Rapamycin ensures high reproducibility, sensitivity, and workflow consistency for cancer, immunology, and mitochondrial disease research.

• LAG-3–TCR Proximity Drives T Cell Suppression in Autoimmunit

  2026-08-06

  Du et al. (2025) reveal that the inhibitory receptor LAG-3 requires close spatial proximity to the T cell receptor (TCR), but not the CD4 co-receptor, to optimally suppress T cell activation and autoimmunity. Their work identifies a novel mechanistic target for selective immunotherapy and demonstrates the effectiveness of a bispecific LAG-3/TCR antibody in preclinical models.

• Arrb2 in Hepatocytes Drives M2 Macrophage Polarization in He

  2026-08-06

  This study reveals that hepatocyte-specific Arrb2 expression promotes M2 macrophage polarization via upregulation of 6-ketoLCA, reducing hepatic ischemia–reperfusion injury (IRI) severity. The findings provide mechanistic insights relevant to improving outcomes in liver transplantation and highlight new avenues for targeted intervention in hepatic IRI models.

• Applied Workflows with Substance P: Tachykinin Neuropeptide

  2026-08-05

  Substance P, a tachykinin neuropeptide, drives high-fidelity pain, inflammation, and immune studies through specific NK-1 receptor engagement. This guide translates fluorescence-based analytics and optimized protocols into actionable workflows, leveraging APExBIO's high-purity Substance P for reproducible CNS and immune research.

• MK 0893: Mechanistic Power and Strategic Roadmap for Glucago

  2026-08-05

  This in-depth feature examines how MK 0893, a potent glucagon receptor antagonist, is transforming the translational landscape for type 2 diabetes research. By integrating mechanistic analysis, comparative benchmarking, and actionable protocol guidance, this article provides translational researchers with a strategic framework for leveraging MK 0893 in both preclinical and clinical studies—while highlighting its unique advantages, evidence-based workflow recommendations, and the future of glucagon receptor modulation.

• TCF25 Orchestrates Lysosomal Cell Fate Under Glucose Starvat

  2026-08-04

  Ren et al. (2025) identify TCF25 as a central nutrient sensor that enhances lysosomal acidification via V-ATPase, coordinating metabolic adaptation and lysosome-dependent cell death during glucose starvation. These findings provide mechanistic insight into how cells balance survival and death under metabolic stress, revealing potential therapeutic targets for metabolic and ischemic disorders.

• T7 RNA Polymerase: Precision RNA Synthesis for Advanced CRIS

  2026-08-04

  T7 RNA Polymerase from APExBIO is the gold standard recombinant enzyme expressed in E. coli for high-fidelity RNA synthesis from T7 promoter-containing templates. This guide demystifies its use in contemporary gene editing, RNA vaccine, and RNAi workflows—highlighting protocol refinements, troubleshooting, and the latest innovations in in vitro transcription for translational research.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-08-03

  This study uncovers the pivotal role of the WNT5a/GSK3/β-catenin signaling axis in controlling adipogenic differentiation of muscle-resident fibro/adipogenic progenitors (FAPs). By integrating pharmacological, single-cell, and in vivo approaches, the research identifies novel regulatory mechanisms underlying intramuscular fat accumulation, with significant implications for muscle disease intervention.

• ST3GAL1-Driven Sialylation Promotes F. nucleatum Adhesion in

  2026-08-03

  A recent study uncovers that ST3GAL1-mediated sialylation on colorectal cancer cells enhances adhesion and colonization by Fusobacterium nucleatum, implicating a novel glycan-dependent mechanism in tumor–microbe interactions. These findings refine our understanding of microbial persistence in the tumor microenvironment and open new avenues for targeting host–microbe dynamics in colorectal cancer.

• T7 RNA Polymerase in Inhalable RNA Therapeutics: Beyond Clas

  2026-08-02

  Explore how T7 RNA Polymerase—an advanced recombinant enzyme expressed in E. coli—enables next-generation in vitro transcription for inhalable RNA therapeutics and tumor microenvironment modulation. This article delivers deeper scientific insights and practical protocol guidance, setting it apart from prior workflow- or troubleshooting-focused resources.

• Asunaprevir (BMS-650032): Translational Leverage in HCV Rese

  2026-08-01

  This thought-leadership article explores the mechanistic, strategic, and translational dimensions of Asunaprevir (BMS-650032) as an advanced hepatitis C virus (HCV) NS3 protease inhibitor. We synthesize recent evidence, highlight protocol parameters, and provide actionable insights for translational researchers, while connecting lessons from epigenetic oncology. This article stands apart from standard product pages by bridging mechanistic virology, host-pathway interplay, and workflow optimization.

• Oral Faropenem Sodium: AMR Implications and Research Insight

  2026-07-31

  This article analyzes the recent literature on faropenem sodium, focusing on its broad-spectrum antimicrobial activity, oral bioavailability, and the emerging risk of antimicrobial resistance (AMR) due to overuse. The findings highlight the molecule’s clinical positioning, resistance trends, and research needs for rational application in infection models.

• iPSC-Based Drug Testing Platform Advances Cystic Fibrosis Re

  2026-07-31

  This study introduces a multimodal platform using iPSC-derived airway epithelial cells to model cystic fibrosis (CF) across diverse CFTR genotypes. The work enables precise assessment of CFTR function and drug response, supporting research into tailored therapies for rare and common CFTR mutations.

16359 records 1/1091 page Next 12345 下5页 Last page